Ascendis Pharma A/S (ASND) — Analyst outlook / Analyst consensus target is. Based on 24 analyst ratings, the consensus is bullish — 22 Buy, 2 Hold.
The consensus price target is $287.17 (low: $250.00, high: $342.00), representing an upside of 14.9% from the current price $249.84.
Analysts estimate Earnings Per Share (EPS) of $-1.06 and revenue of $0.05B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-6.53 vs est $-1.06 (missed -514.4%). 2025: actual $-3.62 vs est $-0.52 (missed -596.3%). Analyst accuracy: 15%.
ASND Stock — 12-Month Price Forecast
$287.17
▲ +14.94% Upside
Average Price Target
Based on 24 Wall Street analysts offering 12-month price targets for Ascendis Pharma A/S, the average price target is $287.17, with a high forecast of $342.00, and a low forecast of $250.00.
The average price target represents a +14.94% change from the last price of $249.84.
Highest Price Target
$342.00
Average Price Target
$287.17
Lowest Price Target
$250.00
ASND Analyst Ratings
Buy
Based on 24 analysts giving stock ratings to Ascendis Pharma A/S in the past 3 months
EPS Estimates — ASND
15%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$6.53
vs Est –$1.06
▼ 83.7% off
2025
Actual –$3.62
vs Est –$0.52
▼ 85.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ASND
15%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.364B
vs Est $0.048B
▲ 86.7% off
2025
Actual $0.692B
vs Est $0.110B
▲ 84.1% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
